Literature DB >> 12183267

Surveillance for antiviral-agent-resistant herpes simplex virus in the general population with recurrent herpes labialis.

Teresa H Bacon1, Ron J Boon, Margaret Schultz, Cheryl Hodges-Savola.   

Abstract

In a general population survey in the United States, the prevalence of antiviral-agent-resistant herpes simplex virus was very low among more than 1,000 isolates from individuals with an episode of recurrent herpes labialis not treated with topical antiviral agents. Two isolates had borderline resistance to acyclovir (0.2%), and all were susceptible to penciclovir.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12183267      PMCID： PMC127455          DOI： 10.1128/AAC.46.9.3042-3044.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialie: a UK-based survey.

Authors:  R J Boon; T H Bacon; H L Robey; T J Coleman; A Connolly; P Crosson; S L Sacks
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

2.  Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group.

Authors:  S L Spruance; T L Rea; C Thoming; R Tucker; R Saltzman; R Boon
Journal:  JAMA       Date:  1997-05-07       Impact factor: 56.272

3.  Perspectives on switching oral acyclovir from prescription to over-the-counter status: report of a consensus panel.

Authors:  M A Sande; D Armstrong; L Corey; W L Drew; D Gilbert; R C Moellering; L G Smith
Journal:  Clin Infect Dis       Date:  1998-03       Impact factor: 9.079

4.  Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial.

Authors:  S L Sacks; R A Thisted; T M Jones; R A Barbarash; D J Mikolich; G E Ruoff; J L Jorizzo; L B Gunnill; D H Katz; M H Khalil; P R Morrow; G J Yakatan; L E Pope; J E Berg
Journal:  J Am Acad Dermatol       Date:  2001-08       Impact factor: 11.527

5.  Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients.

Authors:  S Safrin; T Elbeik; L Phan; D Robinson; J Rush; A Elbaggari; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

6.  Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir.

Authors:  P Collins; M N Ellis
Journal:  J Med Virol       Date:  1993       Impact factor: 2.327

7.  Survey of resistance of herpes simplex virus to acyclovir in northwest England.

Authors:  J Christophers; J Clayton; J Craske; R Ward; P Collins; M Trowbridge; G Darby
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191
  7 in total
  12 in total

Review 1.  Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance.

Authors:  Anthony Griffiths
Journal:  Drug Resist Updat       Date:  2011-09-22       Impact factor: 18.500

Review 2.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 3.  Current management and recommendations for access to antiviral therapy of herpes labialis.

Authors:  Anthony Cunningham; Paul Griffiths; Peter Leone; Adrian Mindel; Rajul Patel; Lawrence Stanberry; Richard Whitley
Journal:  J Clin Virol       Date:  2011-09-01       Impact factor: 3.168

4.  Anti-herpes virus activity of lactobacillus' postbiotics.

Authors:  Neli Vilhelmova-Ilieva; Georgi Atanasov; Lora Simeonova; Lili Dobreva; Kapka Mancheva; Madlena Trepechova; Svetla Danova
Journal:  Biomedicine (Taipei)       Date:  2022-03-01

5.  2-[4,5-Difluoro-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2.

Authors:  Mårten Strand; Koushikul Islam; Karin Edlund; Christopher T Oberg; Annika Allard; Tomas Bergström; Ya-Fang Mei; Mikael Elofsson; Göran Wadell
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

Review 6.  Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

Authors:  Jairam R Lingappa; Connie Celum
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Acute viral infections of the central nervous system in immunocompetent adults: diagnosis and management.

Authors:  Marie Studahl; Lars Lindquist; Britt-Marie Eriksson; Göran Günther; Malin Bengner; Elisabeth Franzen-Röhl; Jan Fohlman; Tomas Bergström; Elisabeth Aurelius
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

8.  Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up.

Authors:  C Danve-Szatanek; M Aymard; D Thouvenot; F Morfin; G Agius; I Bertin; S Billaudel; B Chanzy; M Coste-Burel; L Finkielsztejn; H Fleury; T Hadou; C Henquell; H Lafeuille; M E Lafon; A Le Faou; M C Legrand; L Maille; C Mengelle; P Morand; F Morinet; E Nicand; S Omar; B Picard; B Pozzetto; J Puel; D Raoult; C Scieux; M Segondy; J M Seigneurin; R Teyssou; C Zandotti
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

Review 9.  Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy.

Authors:  Teresa H Bacon; Myron J Levin; Jeffry J Leary; Robert T Sarisky; David Sutton
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

10.  In vitro anti-Herpes simplex virus activity of crude extract of the roots of Nauclea latifolia Smith (Rubiaceae).

Authors:  Manuela Donalisio; Huguette Magnifouet Nana; Rosalie Annie Ngono Ngane; Donatien Gatsing; Alembert Tiabou Tchinda; Roberta Rovito; Valeria Cagno; Cecilia Cagliero; Fabrice Fekam Boyom; Patrizia Rubiolo; Carlo Bicchi; David Lembo
Journal:  BMC Complement Altern Med       Date:  2013-10-16       Impact factor: 3.659
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.